Clone RMP114 is commonly used for in vivo blockade of PD1 signaling in mice, particularly for research in cancer immunotherapy, immune regulation, and mechanistic studies of immune checkpoint pathways.

Key in vivo applications include:

• Cancer Immunotherapy Studies: RMP114 is extensively used in preclinical mouse models (such as syngeneic and genetically engineered models) to block PD1/PDL1 interactions, thereby enhancing antitumor immune responses, reducing tumor growth, and improving survival outcomes.
• Mechanistic Immunology: The antibody is used to investigate the role and regulation of the PD1 pathway in T cell exhaustion, activation, and immune homeostasis.
• Combination Therapies and Tumor Model Benchmarking: RMP114 frequently serves as a benchmark or control antibody in studies comparing different immunotherapeutic strategies, including combinations with other immune checkpoint inhibitors or chemotherapies.
• Functional Immune Assays: Its application includes validating PD1 blockade in vivo by monitoring T cell proliferation, cytokine production, and depletion studies, often via flow cytometry and immunohistochemistry.

Additional notes:

• Isotype and Mechanism: As a rat IgG2a monoclonal antibody, RMP114 can mediate antibodydependent cellular cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC), which may contribute to its efficacy in tumor models.
• Specificity: RMP114 is specific to mouse PD1 and does not crossreact with human PD1, making it unsuitable for translational studies in humanized mice where crossreactivity is required.

In summary, RMP114 is a cornerstone tool for in vivo PD1 blockade in murine studies, with principal utility in preclinical cancer immunotherapy and immune regulation research.

RMP114 is a commonly used monoclonal antibody against mouse PD1, often utilized in immunotherapy research, particularly in in vivo models. Here are some other antibodies or proteins frequently used alongside RMP114:

1. 29F.1A12: This antibody is another antiPD1 monoclonal antibody often used for both in vivo and in vitro studies. It has a higher avidity than RMP114 and can effectively block PD1/PDL1 interactions.

2. J43: Similar to RMP114 and 29F.1A12, J43 is used for blocking PD1 signaling. It is noted for its efficacy in tumor models and is used in both in vivo and in vitro research.

3. PDL1 and PDL2: These are the ligands for PD1, and antibodies targeting them can also be used in studies involving PD1. Commonly used antibodies include 10F.9G2 and MIH6 against PDL1.

4. Other PD1 Agonist Antibodies: While RMP114 exhibits both blocking and agonist activities, other antibodies like RMP130 are recognized for their agonist properties, binding to different regions of the PD1 molecule.

Using these antibodies in combination with RMP114 can provide a comprehensive understanding of PD1 mediated immune responses and their modulation in various experimental settings.

Clone RMP114 is a widely used antimouse PD1 monoclonal antibody in immunooncology research, mainly known for its effectiveness in preclinical models to block the PD1 pathway. Key findings from the scientific literature regarding RMP114 are as follows:

• Proven Efficacy in Tumor Models: RMP114 demonstrates significant antitumor activity in multiple mouse cancer models, including glioma, melanoma, breast cancer, and mesothelioma, especially when combined with other therapies. Tumor suppression rates range from 65% to over 80% in combination settings.

• Benchmark for PD1 Blockade: RMP114 is considered a gold standard for in vivo PD1 blockade studies due to its ability to enhance antitumor immune responses, reduce tumor growth, and improve survival outcomes in syngeneic and genetically engineered mouse models.

• High Specificity and Blocking Activity: It was developed for high affinity and specificity to mouse PD1, selectively blocking the PD1/PDL1 and PD1/PDL2 interactions that suppress T cell function.

• Functional Role: RMP114 primarily acts as a blocking antibody in in vivo systems, efficiently blocking inhibitory signaling but exhibiting minimal agonistic (suppressive) activity, thus aligning with its therapeutic intent to reinvigorate T cell activity.

• Binding Affinity and Comparative Performance: Though effective, RMP114 has a lower binding avidity compared to some other antiPD1 clones such as 1A12; 1A12 outperforms RMP114 at lower concentrations due to higher avidity (IC~50~ for RMP114 is around 3–4 µg/mL, versus ~0.03 µg/mL for 1A12). However, RMP114 outperforms other clones like J43 in tumor growth inhibition and survival in certain models.

• Validated Protocols and Reproducibility: The extensive preclinical literature and wellestablished dosing protocols make RMP114 a reliable and reproducible tool for researchers.

• Antibody Characteristics: RMP114 is a rat IgG2a isotype, developed through hybridoma technology for functional PD1 blockade in mice.

• Limitations and Considerations: Its lack of crossreactivity with human PD1 means it is not suitable for clinical or translational studies involving humanized models, where humanreactive antibodies like EH12.2H7 are preferred. Its lower avidity compared to some other clones can also affect performance in studies requiring minimal antibody concentrations.

• Mechanistic and Immunological Insights: Studies confirm that RMP114 increases cytokine production (e.g., IFNγ) in T cells, restauring antitumor immunity by releasing PD1mediated inhibitory signals.

In summary, RMP114 is a validated and potent tool for in vivo mouse studies on PD1 blockade, valued for its specificity, reproducibility, and welldocumented antitumor effects, though its properties should be carefully matched to the experimental context.

Dosing regimens for the RMP114 clone, an antimouse PD1 antibody, can vary across different mouse models primarily based on the specific experimental objectives and the characteristics of the models used. Here are some general guidelines and considerations:

Typical Dosing Range

• General Dosing Range: The typical dosing range for RMP114 is between 200500 μg per mouse, administered via intraperitoneal (IP) injection every 34 days.

Factors Influencing Dosing Regimens

• Tumor Type and Model: The choice of tumor model, such as MC38 colon carcinoma or B16 melanoma, can influence the dosing regimen. Different tumor models may require adjustments in dosage or frequency to optimize the efficacy of PD1 blockade.
• Immune System Competency: The competency of the mouse's immune system can affect how well the PD1 blockade works. Models with intact immune systems may require specific dosing strategies to avoid adverse effects while maximizing antitumor response.
• Genetic Background: Variations in the genetic background of different mouse strains can influence their response to PD1 blockade. Therefore, dosing may need to be adjusted based on the strain used in the study.

Troubleshooting and Adjustments

• Common Issues: Treatment responses can vary due to differences in tumor models or animal strains. Wellcharacterized models and consistent experimental conditions are crucial to mitigate variability.
• Adverse Effects: Monitoring for adverse effects like autoimmunity or toxicity is important. Strategies such as dose reduction or treatment discontinuation may be necessary.
• AntiDrug Antibodies (ADAs): The development of ADAs against RMP114 can limit its efficacy over time. Intermittent dosing or immunomodulation may help reduce ADA formation.

Overall, while there is a standard dosing range for RMP114, the regimen can be tailored based on the specific needs and characteristics of individual mouse models.